EQS-News: Viromed Medical AG: Further share placements from the holdings of the CEO and founder to support additional financing of ongoing operations
|
EQS-News: Viromed Medical AG
/ Key word(s): Miscellaneous
CORPORATE NEWS Viromed Medical AG: Further share placements from the holdings of the CEO and founder to support additional financing of ongoing operations Rellingen, 25 August 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, plans further sales of shares held by the CEO and founder Uwe Perbandt and his family. The proceeds from the sale are to be used to provide additional financing for ongoing business operations and to strengthen working capital through the granting of loans. In the current year, the Perbandt family has already provided the company with 1.7 million euros to finance working capital, scientific studies and extensive regulatory approval activities. Uwe Perbandt, Chief Executive Officer (CEO) of Viromed Medical AG, explains: “With these planned additional sales, I aim to support the financing of our working capital. In particular, the focus now is on being prepared for further growth through higher purchase volumes and the establishment of a larger inventory. At the same time, we are offering new investors the opportunity to invest in our company. The strategic development of Viromed, as well as our goal of firmly establishing cold plasma technology as an integral part of a wide range of application areas, remain key objectives for the company’s next stage of development.” In order to finance the planned acquisition of relyon plasma GmbH, the Perbandt family is willing to sell some of its shares and reduce its stake in Viromed to as low as 25.1%. The planned reallocations are to be carried out primarily with strategic investors and, to a lesser extent, in an orderly manner on the market, with as little impact on the share price as possible. At the same time, this measure is intended to contribute to a further broadening of the investor base.
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. www.viromed-medical-ag.de
Contact Viromed E-Mail: kontakt@viromed-medical.de
Press contact E-Mail: viromed@kirchhoff.de
25.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| LEI Code: | 894500XR05MYCVCCR171 |
| EQS News ID: | 2387944 |
| End of News | EQS News Service |
|
|
2387944 25.08.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,13 | 5,09 | 8,50 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 4,98 | 2,25 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 442,93 | 44,25 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 4,73 | 1,73 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 420,44 | 33,95 | 94,12 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | -3,09 | 0,60 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -274,84 | 11,87 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | -2,84 | 1,13 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,15 | 0,03 | 0,06 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 138,13 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 65,00 | 0,00 | 0,00 | 325,00 | 13,19 | 122,45 | 27,15 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 30.09.2026 | 22.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -10,65% | +9,26% | +71,05% | +80,56% | +35,42% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
